PROGNOSIS OF CHRONIC MYELOID-LEUKEMIA - STUDIES FROM THE BARCELONA GROUP

被引：2

作者：

ROZMAN, C

CERVANTES, F

ROZMAN, M

URBANOISPIZUA, A

机构：

[1] Postgraduate School of Hematology Farreras Valenti Hospital Clinic, University of Barcelona

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷

关键词：

CHRONIC MYELOID LEUKEMIA; PROGNOSIS; BLAST CRISIS;

D O I：

10.3109/10428199309047866

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Individual and multicenter efforts have facilitated the recognition of different parameters with prognostic value at presentation of chronic myeloid leukemia (CML). Interest is currently focused on the prognostic evaluation of features obtained from molecular analysis, and isolation of data with evalutive predictive value. The site of breakpoint within the M-BCR has been suggested as a prognostic factor in some studies. A recent analysis from our group failed to demonstrate differences in either duration of chronic phase or survival between patients with 5' and 3' breakpoints. We have confirmed in a sequential study that a decrease in the expression of some myeloid differentiation antigens of the blood granulocytes can be a prognostic indicator along CML evolution. Our more recent study, separating blast crises on immunological and molecular grounds, confirms lymphoid cases as a distinct subgroup and shows a trend for an association between megakaryoblastic blast crisis and 3' location of the breakpoint.

引用

页码：63 / 66

页数：4

共 29 条

[1]

Tura S., Baccarani M., Corbelli G., The Italian Cooperative Study Group on Chronic Myeloid Leukaemia, Staging of chronic myeloid leukaemia, Br. J. Haematol., 47, pp. 105-119, (1981)

[2]

Gomez G.A., Sokal J.E., Walsh D., Prognostic features at diagnosis of chronic myelocytic leukemia, Cancer, 47, pp. 2470-2471, (1981)

[3]

Cervantes F., Rozman C., A multivariate analysis of prognostic factors in chronic myeloid leukemia, Blood, 60, pp. 1298-1304, (1982)

[4]

Kantarjian H.M., Smith T.L., Mc Credie K.B., Et al., Clinical myelogenous leukemia: A multivariate analysis of patient characteristics and therapy with survival, Blood, 66, pp. 1326-1335, (1985)

[5]

Sokal J.E., Cox E.B., Baccarani M., Et al., Prognostic discrimination in “good-risk” chronic granulocytic leukemia, Blood, 63, pp. 789-799, (1984)

[6]

Sokal J.E., Baccarani R., Tura S., Et al., Prognostic discrimination among younger patients with chronic granulocytic leukemia: Relevance to bone marrow transplantation, Blood, 66, pp. 1352-1357, (1986)

[7]

Sokal J.E., Gomez G.A., Baccarani M., Et al., Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia, Blood, 72, pp. 294-298, (1988)

[8]

Kantarjian H.M., Keating M.J., Smith T.L., Talpaz M., McCredie K.B., Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia, Am. J. Med., 61, pp. 1441-1446, (1990)

[9]

Gallin J.I., Jacobson R.J., Seligmann B.E., Et al., A neutrophil marker reveals two groups of chronic myelogenous leukemia and its absence may be a marker of disease progression, Blood, 68, pp. 343-346, (1986)

[10]

Todd M.B., Waldron J.A., Jennings T.A., Et al., Loss of myeloid differentiation antigens precedes blastic transformation in chronic myelogenous leukemia, Blood, 70, pp. 122-131, (1987)

← 1 2 3 →